1-5 of 5
Rolf Bruns
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib

Open Access
Christian Rolfo, Aurora O’Brate, Christoph Menzel, Rolf Bruns, Dilafruz Juraeva, Christopher Stroh, Andreas Johne, Paul K. Paik
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF10.
https://doi.org/10.1158/1078-0432.CCR-24-4097
Published: 05 June 2025
View articletitled, Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib
Open the PDF for Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib in another window
Includes: Supplementary data
Journal Articles

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis

Open Access
Chong Kin Liam, Azura Rozila Ahmad, Te-Chun Hsia, Jianying Zhou, Dong-Wan Kim, Ross Andrew Soo, Ying Cheng, Shun Lu, Sang Won Shin, James Chih-Hsin Yang, Yiping Zhang, Jun Zhao, Karin Berghoff, Rolf Bruns, Andreas Johne, Yi-Long Wu
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (10): 1879–1886.
https://doi.org/10.1158/1078-0432.CCR-22-3318
Published: 15 May 2023
View articletitled, Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
Open the PDF for Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis in another window
Includes: Supplementary data
Journal Articles

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

Open Access
Xiuning Le, Hiroshi Sakai, Enriqueta Felip, Remi Veillon, Marina Chiara Garassino, Jo Raskin, Alexis B. Cortot, Santiago Viteri, Julien Mazieres, Egbert F. Smit, Michael Thomas, Wade T. Iams, Byoung Chul Cho, Hye Ryun Kim, James Chih-Hsin Yang, Yuh-Min Chen, Jyoti D. Patel, Christine M. Bestvina, Keunchil Park, Frank Griesinger, Melissa Johnson, Maya Gottfried, Christian Britschgi, John Heymach, Elif Sikoglu, Karin Berghoff, Karl-Maria Schumacher, Rolf Bruns, Gordon Otto, Paul K. Paik
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (6): 1117–1126.
https://doi.org/10.1158/1078-0432.CCR-21-2733
Published: 15 March 2022
View articletitled, Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
Open the PDF for Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice in another window
Includes: Supplementary data
Journal Articles

First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors

Free
Gerald S. Falchook, Razelle Kurzrock, Hesham M. Amin, Wenyuan Xiong, Siqing Fu, Sarina A. Piha-Paul, Filip Janku, Ghazaleh Eskandari, Daniel V. Catenacci, Manfred Klevesath, Rolf Bruns, Uz Stammberger, Andreas Johne, Friedhelm Bladt, Manja Friese-Hamim, Pascal Girard, Samer El Bawab, David S. Hong
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (6): 1237–1246.
https://doi.org/10.1158/1078-0432.CCR-19-2860
Published: 13 March 2020
View articletitled, First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors
Open the PDF for First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer

Free
Maha Hussain, Sylvestre Le Moulec, Claude Gimmi, Rolf Bruns, Josef Straub, Kurt Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (13): 3192–3200.
https://doi.org/10.1158/1078-0432.CCR-15-2512
Published: 30 June 2016
View articletitled, Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data